Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,605.80 +151.02 1.21%
S&P 500 1,333.60 +15.78 1.20%
Nasdaq 2,878.22 +40.69 1.43%
Ticker Volume Price Price Delta
STOXX 50 2,171.60 +23.68 1.10%
FTSE 100 5,393.04 +36.70 0.69%
DAX 6,423.29 +100.10 1.58%
Ticker Volume Price Price Delta
Nikkei 8,657.08 +63.93 0.74%
TOPIX 727.03 +5.92 0.82%
Hang Seng 19,055.50 +254.47 1.35%
Gold 1,582.00 +0.69%
EUR-USD 1.2543 0.0159%
Nasdaq 2,878.22 +1.43%
DJIA 12,605.80 +1.21%
S&P 500 1,333.60 +1.20%
FTSE 100 5,393.04 +0.69%
STOXX 50 2,171.60 +1.10%
DAX 6,423.29 +1.58%
Oil (WTI) 91.90 +1.14%
U.S. 10-year 1.729% -0.009
BAC:US 7.25 +1.44%
FB:US 30.18 -5.42%

American Eagle, Biogen, General Motors, Thor, Quest: U.S. Equity Preview

Shares of the following companies may have unusual moves in U.S. trading on Jan. 23. Stock symbols are in parentheses, and prices are as of 5 p.m. in New York.

American Eagle Outfitters Inc. (AEO) fell 0.7 percent to $13.71. Chief Executive Officer James O’Donnell will resign from the teen retailer. The Pittsburgh-based company named Jay Schottenstein executive chairman.

General Motors Co. (GM) : The National Highway Traffic Safety Administration closed its battery safety investigation of the automaker’s Chevy Volts, saying it doesn’t believe they or other electric vehicles pose a greater risk of fire than gasoline-powered vehicles.

Legacy Reserves LP (LGCY) : The Midland, Texas-based oil company boosted its quarterly dividend to 55 cents a share from 54.5 cents.

Thor Industries Inc. (THO) : The recreational-vehicle maker said it agreed to repurchase 1 million shares at $28.50 each in a private transaction from the estate of Wade F.B. Thompson, co-founder and former chief executive officer of the company.

Quest Diagnostics Inc. (DGX) (DGX US): The Food and Drug Administration authorized the biggest U.S. operator of medical laboratories to offer a new test for infection risk in multiple sclerosis patients taking Elan Corp. (ELN ID) and Biogen Idec Inc. (BIIB)’s Tysabri drug.

Separately, Elan and Biogen Idec won U.S. clearance to modify the label of Tysabri with new safety information that may double the treatment’s worldwide sales.

To contact the reporter on this story: Inyoung Hwang in New York at ihwang7@bloomberg.net.

To contact the editor responsible for this story: Nick Baker at nbaker7@bloomberg.net.

Sponsored Links